Learning Objectives
- Understand the burden of renal disease in patients with diabetes.
- Discuss the renal subgroup data from the EMPA-REG OUTCOMES trial.
- Understand the mechanisms of cardio-renal protection with Empagliflozin.
- Provide clinicians with practical advice about how to incorporate these data into the management algorithm for individuals with diabetes.
Agenda
Click to view video in chapters
| 00:00:00 | Welcome and Introductions Dr. Lawrence A. Leiter |
| 00:03:39 | Why Do We Care About the Kidney in Diabetes? Dr. Christopher Chan |
| 00:14:20 | EMPA-REG OUTCOMES and the Progression of Kidney Disease in Type 2 Diabetes Dr. Bernard Zinman |
| 00:30:08 | Mechanistic Basis of the SGLT2 Renal Benefit Dr. Christopher Chan |
| 00:37:57 | Mechanistic Basis of the SGLT2 Inhibitor Cardiovascular Benefits in the EMPA-REG OUTCOMES Trial Dr. Subodh Verma |
| 00:59:16 | Expert Panel Discussion |
| 01:10:45 | Closing Remarks Dr. Lawrence A. Leiter |
Faculty
Lawrence A. Leiter
MD, FRCPC, FACP, FACE, FAHA
Endocrinologist, St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences, University of Toronto
Christopher T. Chan
MD, FRCPC
Professor of Medicine, University of Toronto
R Fraser Elliott Chair in Home Dialysis
Director, Division of Nephrology, University Health Network
Bernard Zinman
MDCM, FRCPC, FACP
Director, Leadership Sinai Centre for Diabetes
Sam and Judy Pencer Family Chair in Diabetes
Senior Scientist, Lunenfeld-Tanenbaum Research Institute Professor of Medicine, University of Toronto
Subodh Verma
MD, PhD, FRCSC, FAHA
Division of Cardiac Surgery, St. Michael’s Hospital
Professor of Surgery, Pharmacology & Toxicology, University of Toronto
Canada Research Chair in Atherosclerosis
Video Information
- Credit:No Credit Available
- Post Date:September 19, 2016
- Expiry Date:N/A
